Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.82 |
| ▸ | PI4KA | P42356 | 2/20 | 0.82 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.82 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.82 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.82 |
| ▸ | DPP4 | P27487 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.82 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.82 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.82 |
| ▸ | GAPDH | P04406 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.82 |
| ▸ | STAT6 | P42226 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669338 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL14580082 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL29537510 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL14565261 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL939272 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL598131 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL598130 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL4204378 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL7153060 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B | |
| SCHEMBL7153080 | 1.00 | ADORA3 (1.00) | ADORA3POLBADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CUREVAC AG (DE) | 2022-01-06 | — | — | US | claimed |
| EP-1229040-B1 | Nucleoside monophosphate derivative, a processor for their production and their use as immunosuppressive drugs | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2003-09-10 | — | — | EP | claimed |
| EP-1229040-A2 | Nucleoside monophosphate derivative, a processor for their production and their use as immunosuppressive drugs | Heidelberg Pharma Holding GmbH (DE) | 2002-08-07 | — | — | EP | claimed |
| US-6025343-A | Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2000-02-15 | — | — | US | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| US-20260103746-A1 | PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA | TYRIS THERAPEUTICS S L (ES) | 2026-04-16 | — | — | US | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260069718-A1 | Engineered Guide RNAs and Polynucleotides | SHAPE THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| US-5015733-A | Phosphoramidites and oligonucleotides derived therefrom | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1991-05-14 | — | — | US | disclosed |
| US-4849513-A | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069718-A1 | Engineered Guide RNAs and Polynucleotides | SNCA, CDA, UPF1 | ADORA3 772/4885POLB 178/4885ADORA1 1093/4885 |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | ADORA3 2418/4885POLB 224/4885ADORA1 3915/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA3 4335/4885POLB 82/4885ADORA1 4370/4885 |
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CPSF6, CPSF1, RNMT | ADORA3 474/4885POLB 464/4885ADORA1 1472/4885 |
| US-20260103746-A1 | PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA | POLM, POLL, POLB | ADORA3 2990/4885POLB 3/4885ADORA1 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.